Prognostic value of baseline carcinoembryonic antigen and cytokeratin 19 fragment levels in advanced non-small cell lung cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Baek, Ae Rin | - |
dc.contributor.author | Seo, Hyun Jung | - |
dc.contributor.author | Lee, June Hyuk | - |
dc.contributor.author | Park, Sung Woo | - |
dc.contributor.author | Jang, An Soo | - |
dc.contributor.author | Paik, Sang Hyun | - |
dc.contributor.author | Koh, Eun Suk | - |
dc.contributor.author | Shin, Hwa Kyun | - |
dc.contributor.author | Kim, Do Jin | - |
dc.date.accessioned | 2021-08-11T13:44:05Z | - |
dc.date.available | 2021-08-11T13:44:05Z | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 1574-0153 | - |
dc.identifier.issn | 1875-8592 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/6873 | - |
dc.description.abstract | BACKGROUND: Serum carcinoembryonic antigen (CEA) and cytokeratin 19 fragment (CYFRA 21-1) levels are prognostic predictors in non-small cell lung cancer (NSCLC). However, even in patients with the same stage of cancer, the serum levels of those markers often vary. OBJECTIVE: We investigated the association between the initial biomarker levels and prognosis. METHODS: We retrospectively reviewed 445 patients with advanced NSCLC and their baseline serum CEA and CYFRA 21-1 levels. Patients were divided into four groups according to the initial levels of those markers: the NN, HN, NH, and HH group. Kaplan-Meier survival analysis with Log-rank test and Cox proportional hazards regression analysis were performed. RESULTS: The 5-year overall survival (OS) rate in the HN group was the highest (32.2%). Multivariate analyses indicated that the HN group (HR 0.520, 95% CI 0.309-0.878, P = 0.014), female sex (HR 0.685, 95% CI 0.498-0.944, P = 0.021), serum CRP level (HR 1.057, 95% CI 1.034-1.080, P < 0.001), chemotherapy (HR 0.324, 95% CI 0.228-0.460, P < 0.001), and chemotherapy/radiotherapy (HR 0.266, 95% CI 0.171-0.414, P < 0.001) were independent prognostic factors for overall survival. CONCLUSIONS: In advanced NSCLC, patients with baseline high serum CEA but low CYFRA 21-1 level have a significant longer overall survival regardless of clinical stage. | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | IOS Press | - |
dc.title | Prognostic value of baseline carcinoembryonic antigen and cytokeratin 19 fragment levels in advanced non-small cell lung cancer | - |
dc.type | Article | - |
dc.publisher.location | 네델란드 | - |
dc.identifier.doi | 10.3233/CBM-170885 | - |
dc.identifier.scopusid | 2-s2.0-85047309045 | - |
dc.identifier.wosid | 000432010300009 | - |
dc.identifier.bibliographicCitation | Cancer Biomarkers, v.22, no.1, pp 55 - 62 | - |
dc.citation.title | Cancer Biomarkers | - |
dc.citation.volume | 22 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 55 | - |
dc.citation.endPage | 62 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | TUMOR-MARKER | - |
dc.subject.keywordPlus | CYFRA 21-1 | - |
dc.subject.keywordPlus | CEA | - |
dc.subject.keywordPlus | CARCINOMA | - |
dc.subject.keywordAuthor | CEA | - |
dc.subject.keywordAuthor | CYFRA 21-1 | - |
dc.subject.keywordAuthor | tumor marker | - |
dc.subject.keywordAuthor | prognostic factor | - |
dc.subject.keywordAuthor | NSCLC | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.